RT Journal Article
T1 COVID-19 and the impact of arterial hypertension-An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany).
A1 El-Battrawy, Ibrahim
A1 Nuñez-Gil, Ivan J
A1 Abumayyaleh, Mohammad
A1 Estrada, Vicente
A1 Manuel Becerra-Muñoz, Víctor
A1 Uribarri, Aitor
A1 Fernández-Rozas, Inmaculada
A1 Feltes, Gisela
A1 Arroyo-Espliguero, Ramón
A1 Trabattoni, Daniela
A1 López-País, Javier
A1 Pepe, Martino
A1 Romero, Rodolfo
A1 Castro-Mejía, Alex F
A1 Cerrato, Enrico
A1 Capel Astrua, Thamar
A1 D'Ascenzo, Fabrizio
A1 Fabregat-Andres, Oscar
A1 Signes-Costa, Jaime
A1 Marín, Francisco
A1 Buonsenso, Danilo
A1 Bardají, Alfredo
A1 Jesús Tellez, María
A1 Fernández-Ortiz, Antonio
A1 Macaya, Carlos
A1 Akin, Ibrahim
K1 COVID
K1 hypertension
AB A systematic analysis of concomitant arterial hypertension in COVID-19 patients and the impact of angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) have not been studied in a large multicentre cohort yet. We conducted a subanalysis from the international HOPE Registry (https://hopeprojectmd.com, NCT04334291) comparing COVID-19 in presence and absence of arterial hypertension. Out of 5837 COVID-19 patients, 2850 (48.8%) patients had the diagnosis arterial hypertension. 1978/2813 (70.3%) patients were already treated with ACEI or ARBs. The clinical outcome of the present subanalysis included all-cause mortality over 40 days of follow-up. Patients with arterial hypertension suffered significantly more from different complications including respiratory insufficiency (60.8% vs 39.5%), heart failure (9.9% vs 3.1%), acute kidney injury (25.3% vs 7.3%), pneumonia (90.6% vs 86%), sepsis (14.7% vs 7.5%), and bleeding events (3.6% vs 1.6%). The mortality rate was 29.6% in patients with concomitant arterial hypertension and 11.3% without arterial hypertension (P  The mortality rate and in-hospital complications might be increased in COVID-19 patients with a concomitant history of arterial hypertension. The history of ACEI or ARBs treatments does not seem to impact the outcome of these patients.
YR 2021
FD 2021-08-19
LK http://hdl.handle.net/10668/18392
UL http://hdl.handle.net/10668/18392
LA en
DS RISalud
RD Apr 11, 2025